Low incidence of opportunistic Infections in SLE Patients treated with Cyclophosphamide and Steroids in a Tertiary care setting
Main Article Content
Abstract
Abstract
Background:
Infection is common cause of morbidity and mortality in SLE. Our objective was to determine incidence and types of infections, particularly opportunistic infections, in SLE patients receiving cyclophosphamide, and to identify contribution of variables like demographics, steroid, other immunosuppressives, white blood cell and absolute neutrophil count to infection risk.
Patients and Methods:
We did retrospective chart review of SLE patients in our institute over last 10 years, who received minimum six cyclophosphamide infusions. Types of infection, cumulative steroid dose, and maintenance medications were recorded. Statistical analyses were done using SAS software.
Results:
87.1% of the 31 patients were female. Mean age was 37.9 years, 48.4% Hispanic, 25.8% African American, 6.4% Asian and 19.4% were Caucasian. No one was on PJP prophylaxis. There were 42 episodes of infection in 31 patients. Different infections were UTI, URI, line sepsis, bacterial pneumonia, PJP, mucocutaneous infections and viral gastroenteritis. Infection frequency was significantly higher among Asians compared to Caucasians (p =0.0152). Infection rate was significantly higher during cyclophosphosphamide induction phase (65.9%) compared to maintenance phase (34.1%) (p value=0.0041). Infection rate was higher with higher cumulative steroid dose and in patients on quarterly cyclophosphamide infusion compared to those on oral azathioprine or mycophenolate mofetil. No association found between baseline WBC or ANC and infection rate.
Conclusion:
We found higher infection rates among Asians and in patients with higher cumulative steroid dose. Single incidence of PJP noted despite absence of prophylaxis. Quarterly cyclophosphamide was associated with higher infection rates. Larger prospective studies are needed to confirm our results.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Pryor BD, Bologna SG, Kahl LE (1996) Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39 (9):1475-82
2. Zandman-Goddard G, Shoenfeld Y (2005) Infections and SLE. Autoimmunity 38:473-85. doi:10.1080/08916930500285352
3. Noel V, Lortholary O, Casassus P, Cohen P, Genereau T, Andre MH, et al. (2001) Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 60:1141-4
4. Feldman CH, Hiraki LT, Winkelmayer WC, Marty FM, Franklin JM, Kim SC, et al (2015) Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 67:1577-85. doi:10.1002/art.39070
5. Zonana-Nacach A, Camargo-Coronel A, Yanez P, Sanchez L, Jimenez-Balderas FJ, Fraga A (2001) Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus 10:505-10
6. Gladman DD, Hussain F, Ibanez D, Urowitz MB (2002) The nature and outcome of infection in systemic lupus erythematosus. Lupus 11:234-9
7. Yuhara T, Takemura H, Akama T, Suzuki H, Yamane K, Kashiwagi H (1996) Predicting infection in hospitalized patients with systemic lupus erythematosus. Intern Med 35:629-36
8. Bosch X, Guilabert A, Pallares L, Cerveral R, Ramos-Casals M, Bove A, et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15:584-9
9. Gupta D, Zachariah A, Roppelt H, Patel AM, Gruber BL (2008) Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature. J Clin Rheumatol 14:267-72. doi:10.1097/RHU.0b013e31817a7e30
10. Austin HA, 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. The New England journal of medicine 314:614-9. doi:10.1056/NEJM198603063141004
11. de Groot K, Adu D, Savage CO, Euvas (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 16:2018-27
12. Schimmer BP PK (2006) The Pharmacological Basis of Therapeutics. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones, 11th ed edn.,
13. Tektonidou MG, Wang Z, Dasgupta A, Ward MM (2015) Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011. Arthritis care & research 67:1078-85. doi:10.1002/acr.22575
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and rheumatism 25:1271-7
15. Iliopoulos AG, Tsokos GC (1996) Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 25:318-36
16. Mok MY, Ip WK, Lau CS, Lo Y, Wong WH, Lau YL (2007) Mannose-binding lectin and susceptibility to infection in Chinese patients with systemic lupus erythematosus. J Rheumatol 34:1270-6
17. Bultink IE, Hamann D, Seelen MA, Hart MH, Dijkmans BA, Daha MR, et al (2006) Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Res Ther 8:R183. doi:10.1186/ar2095
18. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcon GS, et al (2013) Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 65:753-63. doi:10.1002/art.37795
19. Fernandez M, Alarcon GS, Calvo-Alen J, Andrade R, McGwin G, Jr., Vila LM, et al (2007) A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 57:576-84. doi:10.1002/art.22672
20. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA (1997) Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 6:254-7
21. Hellmann DB, Petri M, Whiting-O'Keefe Q (1987) Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 66:341-8
22. Petri M, Allbritton J (1992) Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol 19:265-9
23. Escalante A, Stimmler MM (1992) Trimethoprim-sulfamethoxasole induced meningitis in systemic lupus erythematosus. J Rheumatol 19:800-2
24. Muller MP, Richardson DC, Walmsley SL (2001) Trimethoprim-sulfamethoxazole induced aseptic meningitis in a renal transplant patient. Clin Nephrol 55:80-4